| Sumario: | Guselkumab (Tremfya) is a fully human immunoglobulin G1 lambda (IgG1a) monoclonal antibody that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. Levels of IL-23 are elevated in the skin of patients with plaque psoriasis and guselkumab exerts its clinical effects in plaque psoriasis through blockade of the IL-23 cytokine pathway. The proposed indication submitted to Health Canada for guselkumab is for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The proposed recommended dose is 100 mg to be given as subcutaneous (SC) injection at week 0 and week 4, followed by maintenance dosing every eight weeks thereafter. The price is 3,060 per 100 mg/mL prefilled syringe.
|
|---|
